Skip to main content

Congress of Clinical Rheumatology (CCR) East, 2025

Filter
Close
Content type:
Bimekizumab Maintained Efficacy Responses in Patients With Active Psoriatic Arthritis: Up to 2-Year Results from Two Phase 3 Studies
Gladman D. Dafna, Walsh A. Jessica, Joseph F. Merola, et al.
Poster
Achieving Greater Disease Control Criteria was Associated with Improved Work Productivity in Patients with Psoriatic Arthritis up to 2 Years
Walsh A. Jessica, Gladman D. Dafna, Laure Gossec, et al.
Poster
Achievement of Remission Defined by Absence of Objective Signs of Inflammation Versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies
Rahman Proton, Gensler S. Lianne, Marzo-Ortega Helena, et al.
Poster
Sustained Symptom Improvement in Psoriatic Arthritis with 2-Year Bimekizumab Treatment Based on Routine Assessment of Patient Index Data 3
Kavanaugh Arthur, M. Elaine Husni, Ogdie Alexis, et al.
Poster